nach oben

Journal of Nephrology

Erschienen in:

26.11.2021 | COVID-19 | Review Zur Zeit gratis

The innate immune system in human kidney inflammaging

verfasst von: Vincenzo Sepe, Carmelo Libetta, Marilena Gregorini, Teresa Rampino

Erschienen in: Journal of Nephrology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Elderly individuals with chronic disorders tend to develop inflammaging, a condition associated with elevated levels of blood inflammatory markers, and increased susceptibility to chronic disease progression. Native and adaptive immunity are both involved in immune system senescence, kidney fibrosis and aging. The innate immune system is characterized by a limited number of receptors, constantly challenged by self and non-self stimuli. Circulating and kidney resident myeloid and lymphoid cells are all equipped with pattern recognition receptors (PRRs). Recent reports on PRRs show kidney overexpression of toll-like receptors (TLRs) in inflammaging autoimmune renal diseases, vasculitis, acute kidney injury and kidney transplant rejection. TLR upregulation leads to proinflammatory cytokine induction, fibrosis, and chronic kidney disease progression. TLR2 blockade in a murine model of renal ischemia reperfusion injury prevented the escape of natural killer cells and neutrophils by inflammaging kidney injury. Tumor necrosis factor-α blockade in endothelial cells with senescence-associated secretory phenotype significantly reduced interleukin-6 release. These findings should encourage experimental and translational clinical trials aimed at modulating renal inflammaging by native immunity blockade.

Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14(10):576–590. https://doi.org/10.1038/s41574-018-0059-4CrossRefPubMed

Sepe V, Gregorini M, Rampino T, Esposito P, Coppo R, Galli F, Libetta C (2019) Vitamin E-loaded membrane dialyzers reduce hemodialysis inflammaging. BMC Nephrol 20(1):412. https://doi.org/10.1186/s12882-019-1585-6CrossRefPubMedPubMedCentral

Loeser RF, Collins JA, Diekman BO (2016) Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol 12(7):412–420. https://doi.org/10.1038/nrrheum.2016.65CrossRefPubMedPubMedCentral

Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, Cuzzocrea S, Zappia M, Giordano J, Calabrese EJ, Franceschi C (2018) Aging and Parkinson’s disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med 115:80–91. https://doi.org/10.1016/j.freeradbiomed.2017.10.379CrossRefPubMed

Meftahi GH, Jangravi Z, Sahraei H, Bahari Z (2020) The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: The contribution of “Inflame-Aging.” Inflamm Res. https://doi.org/10.1007/s00011-020-01372-8CrossRefPubMedPubMedCentral

Heath JJ, Grant MD (2020) The immune response against human cytomegalovirus links cellular to systemic senescence. Cells 9(3):766. https://doi.org/10.3390/cells9030766CrossRef

Bottazzi B, Riboli E, Mantovani A (2018) Aging, inflammation and cancer. Semin Immunol 40:74–82. https://doi.org/10.1016/j.smim.2018.10.011CrossRefPubMed

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G (2000) Inflamm-aging. an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.xCrossRefPubMed

Santoro A, Bientinesi E, Monti D (2021) Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. https://doi.org/10.1016/j.arr.2021.101422CrossRefPubMed

10.

Krishna C, Chowell D, Gönen M, Elhanati Y, Timothy AC (2020) Genetic and environmental determinants of human TCR repertoire diversity. Immun Ageing 17:26. https://doi.org/10.1186/s12979-020-00195-9CrossRefPubMedPubMedCentral

11.

McDaniel MM, Meibers HE, Pasare C (2021) Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information. Curr Opin Immunol 73:25–33. https://doi.org/10.1016/j.coi.2021.07.013CrossRefPubMed

12.

Yue Z, Nie L, Zhang P, Chen Q, Lv Q, Wang Q (2021) Tissue-resident macrophage inflammaging aggravates homeostasis dysregulation in age-related diseases. Cell Immunol 361:104278. https://doi.org/10.1016/j.cellimm.2020.104278CrossRefPubMed

13.

Shaw AC, Goldstein DR, Montgomery RR (2013) Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13(12):875–887. https://doi.org/10.1038/nri3547CrossRefPubMedPubMedCentral

14.

Akar-Ghibril N (2021) Defects of the innate immune system and related immune deficiencies. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-021-08885-yCrossRefPubMed

15.

Takeda K (2005) Evolution and integration of innate immune recognition systems: the Toll-like receptors. J Endotoxin Res 11(1):51–55. https://doi.org/10.1179/096805105225006687CrossRefPubMed

16.

Olivieri F, Procopio AD, Montgomery RR (2014) Effect of aging on microRNAs and regulation of pathogen recognition receptors. Curr Opin Immunol 29:29–37. https://doi.org/10.1016/j.coi.2014.03.006CrossRefPubMed

17.

Duez H, Pourcet B (2021) Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway. Front Endocrinol (Lausanne) 12:630536. https://doi.org/10.3389/fendo.2021.630536CrossRef

18.

Latz E, Duewell P (2018) NLRP3 inflammasome activation in inflammaging. Semin Immunol 40:61–73. https://doi.org/10.1016/j.smim.2018.09.001CrossRefPubMed

19.

Kielar M, Gala-Błądzińska A, Dumnicka P, Ceranowicz P, Kapusta M, Naumnik B, Kubiak G, Kuźniewski M, Kuśnierz-Cabala B (2021) Complement components in the diagnosis and treatment after kidney transplantation-Is there a missing link? Biomolecules 11(6):773. https://doi.org/10.3390/biom11060773CrossRefPubMedPubMedCentral

20.

Collins SE, Mossman KL (2014) Danger, diversity and priming in innate antiviral immunity. Cytokine Growth Factor Rev 25(5):525–531. https://doi.org/10.1016/j.cytogfr.2014.07.002CrossRefPubMed

21.

Jacquet A, Robinson C (2020) Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens. Allergy 75(1):33–53. https://doi.org/10.1111/all.13940CrossRefPubMed

22.

Cui B, Lin H, Yu J, Yu J, Hu Z (2019) Autophagy and the immune response. Adv Exp Med Biol 1206:595–634. https://doi.org/10.1007/978-981-15-0602-4_27CrossRefPubMedPubMedCentral

23.

Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) Release mechanisms of major DAMPs. Apoptosis. https://doi.org/10.1007/s10495-021-01663-3CrossRefPubMedPubMedCentral

24.

El-Naccache DW, Haskó G, Gause WC (2021) Early events triggering the initiation of a Type 2 immune response. Trends Immunol 42(2):151–164. https://doi.org/10.1016/j.it.2020.11.006CrossRefPubMed

25.

Degn SE, Thiel S (2013) Humoral pattern recognition and the complement system. Scand J Immunol 78(2):181–193. https://doi.org/10.1111/sji.12070CrossRefPubMed

26.

Tesch GH (2017) Diabetic nephropathy—Is this an immune disorder? Clin Sci (Lond) 131(16):2183–2199. https://doi.org/10.1042/CS20160636CrossRef

27.

Nie L, Cai SY, Shao JZ, Chen J (2018) Toll-Like Receptors, associated biological roles, and signaling networks in non-mammals. Front Immunol 9:1523. https://doi.org/10.3389/fimmu.2018.01523CrossRefPubMedPubMedCentral

28.

Lorenz G, Lech M, Anders HJ (2017) Toll-like Receptor activation in the pathogenesis of lupus nephritis. Clin Immunol 185:86–94. https://doi.org/10.1016/j.clim.2016.07.015CrossRefPubMed

29.

Arnold-Schrauf C, Berod L, Sparwasser T (2015) Dendritic Cell Specific targeting of MyD88 signalling pathways in vivo. Eur J Immunol 45(1):32–39. https://doi.org/10.1002/eji.201444747CrossRefPubMed

30.

O’Reilly S (2018) Toll Like Receptors in systemic sclerosis: an emerging target. Immunol Lett 195:2–8. https://doi.org/10.1016/j.imlet.2017.09.001CrossRefPubMed

31.

Negishi H, Taniguchi T, Yanai H (2018) The interferon (IFN) class of cytokines and the IFN Regulatory Factor (IRF) Transcription Factor family. Cold Spring Harb Perspect Biol 10(11):a028423. https://doi.org/10.1101/cshperspect.a028423CrossRefPubMedPubMedCentral

32.

Almuttaqi H, Udalova IA (2019) Advances and challenges in targeting IRF5, a key regulator of inflammation. FEBS J 286(9):1624–1637. https://doi.org/10.1111/febs.14654CrossRefPubMed

33.

Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Wymer DT, Yamabe H, Mathieson PW, Saleem MA, Garin EH, Johnson RJ (2012) Toll-like Receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway. Nephrol Dial Transpl 27(1):81–89. https://doi.org/10.1093/ndt/gfr271CrossRef

34.

Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-Beckmann U, Röschmann K, Jung G, Wiesmüller KH, Ulmer AJ (2004) Signaling Danger: Toll-Like receptors and their potential roles in Kidney Disease. J Am Soc Nephrol 15(4):854–867. https://doi.org/10.1097/01.asn.0000121781.89599.16CrossRef

35.

Upadhyay R, Ying WZ, Nasrin Z, Safah H, Jaimes EA, Feng W, Sanders PW, Batuman V (2020) Free light chains injure proximal tubule cells through STAT1-HMGB1-TLR axis. JCI Insight. https://doi.org/10.1172/jci.insight.137191CrossRefPubMedPubMedCentral

36.

O’Sullivan KM, Ford SL, Longano A, Kitching AR, Holdsworth SR (2018) Intrarenal Toll-like Receptor 4 and Toll-like Receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis. Am J Physiol Renal Physiol 315(5):F1283–F1294. https://doi.org/10.1152/ajprenal.00040.2018CrossRefPubMedPubMedCentral

37.

Wang H, Gou SJ, Zhao MH, Chen M (2014) The expression of Toll-like Receptors 2, 4 and 9 in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol 177(3):603–610. https://doi.org/10.1111/cei.12365CrossRefPubMedPubMedCentral

38.

Sharbafi MH, Assadiasl S, Pour-Reza-Gholi F, Barzegari S, Mohammadi Torbati P, Samavat S, Nicknam MH, Amirzargar A (2019) TLR-2, TLR-4 and MyD88 genes expression in renal transplant acute and chronic rejections. Int J Immunogenet 46(6):427–436. https://doi.org/10.1111/iji.12446CrossRefPubMed

39.

Hosseinzadeh M, Ahmadpoor P, Yekaninejad MS, Pourrezagholi F, Foroughi F, Ghorbanpour M, Barabadi M, Shahbaz SK, Solgi G, Amirzargar A (2018) Expression patterns of Toll Like Receptor (TLR)-2, TLR-4 and myeloid differentiation primary response gene 88 (MYD88) in renal transplant patients developing allograft dysfunction; A cohort study. Transpl Immunol 48:26–31. https://doi.org/10.1016/j.trim.2018.02.005CrossRefPubMed

40.

Raby AC, Colmont CS, Kift-Morgan A, Köhl J, Eberl M, Fraser D, Topley N, Labéta MO (2017) Toll-Like Receptors 2 and 4 are potential therapeutic targets in peritoneal dialysis-associated fibrosis. J Am Soc Nephrol 28(2):461–478. https://doi.org/10.1681/ASN.2015080923CrossRefPubMed

41.

Elloumi N, Fakhfakh R, Ayadi L, Sellami K, Abida O, Ben Jmaa M, Sellami T, Kammoun K, Masmoudi H (2017) The increased expression of Toll-Like Receptor 4 in renal and skin lesions in lupus erythematosus. J Histochem Cytochem 65(7):389–398. https://doi.org/10.1369/0022155417709234CrossRefPubMedPubMedCentral

42.

Imaizumi T, Hayakari R, Watanabe S, Aizawa T, Matsumiya T, Yoshida H, Tsuruga K, Kawaguchi S, Tanaka H (2017) Cylindromatosis (CYLD), a deubiquitinase, attenuates inflammatory signaling pathways by activating Toll-Like Receptor 3 in human mesangial cells. Kidney Blood Press Res 42(5):942–950. https://doi.org/10.1159/000485084CrossRefPubMed

43.

Mishra OP, Kumar R, Narayan G, Srivastava P, Abhinay A, Prasad R, Singh A, Batra VV (2017) Toll-like Receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome. Pediatr Nephrol 32(8):1355–1361. https://doi.org/10.1007/s00467-017-3613-8CrossRefPubMed

44.

Conti F, Spinelli FR, Truglia S, Miranda F, Alessandri C, Ceccarelli F, Bombardieri M, Giannakakis K, Valesini G (2016) Kidney expression of Toll Like Receptors in lupus nephritis: quantification and clinicopathological correlations. Mediators Inflamm 2016:7697592. https://doi.org/10.1155/2016/7697592CrossRefPubMedPubMedCentral

45.

Jamin A, Dehoux L, Dossier C, Fila M, Heming N, Monteiro RC, Deschênes G (2015) Toll-like Receptor 3 expression and function in childhood idiopathic nephrotic syndrome. Clin Exp Immunol 182(3):332–345. https://doi.org/10.1111/cei.12659CrossRefPubMedPubMedCentral

46.

Nakano D, Kitada K, Wan N, Zhang Y, Wiig H, Wararat K, Yanagita M, Lee S, Jia L, Titze JM, Nishiyama A (2020) Lipopolysaccharide induces filtrate leakage from renal tubular lumina into the interstitial space via proximal tubular Toll-like receptor 4-dependent pathway and limits sensitivity to fluid therapy in mice. Kidney Int 97(5):904–912. https://doi.org/10.1016/j.kint.2019.11.024CrossRefPubMed

47.

Wei Q (2020) Novel strategy for septic acute kidney injury rescue: maintenance of the tubular integrity. Kidney Int 97(5):847–849. https://doi.org/10.1016/j.kint.2019.12.024CrossRefPubMed

48.

Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND (2010) Leukocyte Toll-Like Receptor expression in end-stage kidney disease. Am J Nephrol 31(3):247–254. https://doi.org/10.1159/000276764CrossRefPubMed

49.

Frieri M, Samih MA, Dzhindzhikhashvili M, Liu H, Balsam L, Rubinstein S (2012) Toll-like Receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol Nov-Dec 25(6):1041–1046. https://doi.org/10.5301/jn.5000091CrossRef

50.

Elloumi N, Fakhfakh R, Abida O, Ayadi L, Marzouk S, Hachicha H, Fourati M, Bahloul Z, Mhiri MN, Kammoun K, Masmoudi H (2017) Relevant genetic polymorphisms and kidney expression of Toll-like Receptor (TLR)-5 and TLR-9 in lupus nephritis. Clin Exp Immunol 190(3):328–339. https://doi.org/10.1111/cei.13022CrossRefPubMedPubMedCentral

51.

Lee SM, Kok KH, Jaume M, Cheung TK, Yip TF, Lai JC, Guan Y, Webster RG, Jin DY, Peiris JM (2014) Toll-like Receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci USA 111(10):3793–3798. https://doi.org/10.1073/pnas.1324266111CrossRefPubMedPubMedCentral

52.

Hari P, Millar FR, Tarrats N, Birch J, Quintanilla A, Rink CJ, Fernández-Duran I, Muir M, Finch AJ, Brunton VG, Passos JF, Morton JP, Boulter L, Acosta JC (2019) The innate immune sensor Toll-like Receptor 2 controls the senescence-associated secretory phenotype. Sci Adv 5(6):eaaw0254. https://doi.org/10.1126/sciadv.aaw0254CrossRefPubMedPubMedCentral

53.

Pasparakis M, Vandenabeele P (2015) Necroptosis and its role in inflammation. Nature 517(7534):311–320. https://doi.org/10.1038/nature14191CrossRefPubMed

54.

Xi Y, Shao F, Bai XY, Cai G, Lv Y, Chen X (2014) Changes in the expression of the Toll-like receptor system in the aging rat kidneys. PLoS ONE 9(5):e96351. https://doi.org/10.1371/journal.pone.0096351CrossRefPubMedPubMedCentral

55.

Drouin M, Saenz J, Chiffoleau E (2020) C-type lectin-like receptors: Head or tail in cell death immunity. Front Immunol 11:251. https://doi.org/10.3389/fimmu.2020.00251CrossRefPubMedPubMedCentral

56.

Chiffoleau E (2018) C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front Immunol 9:227. https://doi.org/10.3389/fimmu.2018.00227CrossRefPubMedPubMedCentral

57.

Hadaya K, de Rham C, Bandelier C, Bandelier C, Ferrari-Lacraz S, Jendly S, Berney T, Buhler L, Kaiser L, Seebach JD, Tiercy JM, Martin PY, Villard J (2008) Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transpl 8(12):2674–2683. https://doi.org/10.1111/j.1600-6143.2008.02431.xCrossRef

58.

Swanson KV, Deng M, Ting JP (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 19(8):477–489. https://doi.org/10.1038/s41577-019-0165-0CrossRefPubMedPubMedCentral

59.

Mulay SR (2019) Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int 96(1):58–66. https://doi.org/10.1016/j.kint.2019.01.014CrossRefPubMed

60.

Hutton HL, Ooi JD, Holdsworth SR, Kitching AR (2016) The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton) 21(9):736–744. https://doi.org/10.1111/nep.12785CrossRef

61.

Anders HJ (2007) Innate pathogen recognition in the kidney: toll-like receptors, NOD-like receptors, and RIG-like helicases. Kidney Int 72(9):1051–1056. https://doi.org/10.1038/sj.ki.5002436CrossRefPubMed

62.

Suzuki K, Imaizumi T, Tsugawa K, Ito E, Tanaka H (2007) Expression of retinoic acid-inducible gene-I in lupus nephritis. Nephrol Dial Transpl 22(8):2407–2409. https://doi.org/10.1093/ndt/gfm175CrossRef

63.

PrabhuDas MR, Baldwin CL, Bollyky PL, Bowdish DME, Drickamer K, Febbraio M, Herz J, Kobzik L, Krieger M, Loike J, McVicker B, Means TK, Moestrup SK, Post SR, Sawamura T, Silverstein S, Speth RC, Telfer JC, Thiele GM, Wang XY, Wright SD, El Khoury J (2017) A consensus definitive classification of scavenger receptors and their roles in health and disease. J Immunol 198(10):3775–3789. https://doi.org/10.4049/jimmunol.1700373CrossRefPubMed

64.

Yang X, Okamura DM, Lu X, Chen Y, Moorhead J, Varghese Z, Ruan XZ (2017) CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol 13(12):769–781. https://doi.org/10.1038/nrneph.2017.126CrossRefPubMed

65.

Zhang Y, Ma Y, Zhang C, Zhang Y, Zhuang R, Liu B, Yi J, Jin B (2015) Soluble scavenger receptor CD163 is associated with severe acute kidney injury in patients with hantaan virus infection. Viral Immunol 28(4):241–246. https://doi.org/10.1089/vim.2014.0112CrossRefPubMed

66.

O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, O’Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O’Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O’Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA (2016) Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27(9):2906–2916. https://doi.org/10.1681/ASN.2015050511CrossRefPubMedPubMedCentral

67.

Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD, Carrero JJ, Ortiz A (2014) CXCL16 in kidney and cardiovascular injury. Cytokine Growth Factor Rev 25(3):317–325. https://doi.org/10.1016/j.cytogfr.2014.04.002CrossRefPubMed

68.

Franzin R, Stasi A, Fiorentino M, Stallone G, Cantaluppi V, Gesualdo L, Castellano G (2020) Inflammaging and complement system: a link between acute kidney injury and chronic graft damage. Front Immunol 11:734. https://doi.org/10.3389/fimmu.2020.00734CrossRefPubMedPubMedCentral

69.

Stewart BJ, Ferdinand JR, Young MD, Mitchell TJ, Loudon KW, Riding AM, Richoz N, Frazer GL, Staniforth JUL, Vieira Braga FA, Botting RA, Popescu DM, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Polanski K, Efremova M, Green K, Del Castillo V-H, Guzzo C, Collord G, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Lindsay S, Bajenoff M, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Behjati S, Clatworthy MR (2019) Spatiotemporal immune zonation of the human kidney. Science 365(6460):1461–1466. https://doi.org/10.1126/science.aat5031CrossRefPubMedPubMedCentral

70.

Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J (2014) Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat Rev Nephrol 10(11):625–643. https://doi.org/10.1038/nrneph.2014.170CrossRefPubMedPubMedCentral

71.

Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E (2021) Mechanisms of macrophage plasticity in the tumor environment: manipulating activation state to improve outcomes. Front Immunol 12:642285. https://doi.org/10.3389/fimmu.2021.642285CrossRefPubMedPubMedCentral

72.

Vegting Y, Vogt L, Anders HJ, de Winther MPJ, Bemelman FJ, Hilhorst ML (2021) Monocytes and macrophages in ANCA-associated vasculitis. Autoimmun Rev 20(10):102911. https://doi.org/10.1016/j.autrev.2021.102911CrossRefPubMed

73.

Zhang H, Li Z, Li W (2021) M2 macrophages serve as critical executor of innate immunity in chronic allograft rejection. Front Immunol 12:648539. https://doi.org/10.1016/10.3389/fimmu.2021.648539CrossRefPubMedPubMedCentral

74.

Bonavia A, Singbartl K (2018) A review of the role of immune cells in acute kidney injury. Pediatr Nephrol 33(10):1629–1639. https://doi.org/10.1007/s00467-017-3774-5CrossRefPubMed

75.

Cao Q, Harris DC, Wang Y (2015) Macrophages in kidney injury, inflammation, and fibrosis. Physiology (Bethesda) 30(3):183–194. https://doi.org/10.1152/physiol.00046.2014CrossRef

76.

Meng XM, Mak TS, Lan HY (2019) Macrophages in renal fibrosis. Adv Exp Med Biol 1165:285–303. https://doi.org/10.1007/978-981-13-8871-2_13CrossRefPubMed

77.

Rauen T, Floege J (2017) Inflammation in IgA nephropathy. Pediatr Nephrol 32(12):2215–2224. https://doi.org/10.1007/s00467-017-3628-1CrossRefPubMed

78.

Hu W, Lin J, Lian X, Yu F, Liu W, Wu Y, Fang X, Liang X, Hao W (2019) M2a and M2b macrophages predominate in kidney tissues and M2 subpopulations were associated with the severity of disease of IgAN patients. Clin Immunol 205:8–15. https://doi.org/10.1016/j.clim.2019.05.005CrossRefPubMed

79.

Maria NI, Davidson A (2017) Renal macrophages and dendritic cells in SLE nephritis. Curr Rheumatol Rep 19(12):81. https://doi.org/10.1007/s11926-017-0708-yCrossRefPubMed

80.

Ikezumi Y, Suzuki T, Yamada T, Hasegawa H, Kaneko U, Hara M, Yanagihara T, Nikolic-Paterson DJ, Saitoh A (2015) Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury. Pediatr Nephrol 30(6):1007–1017. https://doi.org/10.1007/s00467-014-3023-0CrossRefPubMed

81.

Meissner M, Viehmann SF, Kurts C (2019) DAMPening sterile inflammation of the kidney. Kidney Int 95(3):489–491. https://doi.org/10.1016/j.kint.2018.12.007CrossRefPubMed

82.

Nakazawa D, Marschner JA, Platen L, Anders HJ (2018) Extracellular traps in kidney disease. Kidney Int 94(6):1087–1098. https://doi.org/10.1016/j.kint.2018.08.035CrossRefPubMed

83.

Nakazawa D, Kumar SV, Marschner J, Desai J, Holderied A, Rath L, Kraft F, Lei Y, Fukasawa Y, Moeckel GW, Angelotti ML, Liapis H, Anders HJ (2017) Histones and neutrophil extracellular traps enhance tubular necrosis and remote organ injury in ischemic AKI. J Am Soc Nephrol 28(6):1753–1768. https://doi.org/10.1681/ASN.2016080925CrossRefPubMedPubMedCentral

84.

Mulay SR, Kumar SV, Lech M, Desai J, Anders HJ (2016) How kidney kell death induces renal necroinflammation. Semin Nephrol 36(3):162–173. https://doi.org/10.1016/j.semnephrol.2016.03.004CrossRefPubMed

85.

Turner JE, Rickassel C, Healy H, Kassianos AJ (2019) Natural killer cells in kidney health and disease. Front Immunol 10:587. https://doi.org/10.3389/fimmu.2019.00587CrossRefPubMedPubMedCentral

86.

Bahl D, Haddad Z, Datoo A, Qazi YA (2019) Delayed graft function in kidney transplantation. Curr Opin Organ Transpl 24(1):82–86. https://doi.org/10.1097/MOT.0000000000000604CrossRef

87.

Gómez-Massa E, Talayero P, Utrero-Rico A, Laguna-Goya R, Andrés A, Mancebo E, Leivas A, Polanco-Fernández N, Justo I, Jimenez-Romero C, Pleguezuelo D, Paz-Artal E (2020) Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients—a single centre cohort study. Transpl Int 33(4):402–413. https://doi.org/10.1111/tri.13567CrossRefPubMed

88.

Victorino F, Sojka DK, Brodsky KS, McNamee EN, Masterson JC, Homann D, Yokoyama WM, Eltzschig HK, Clambey ET (2015) Tissue-resident NK cells mediate ischemic kidney injury and are not depleted by anti-asialo-GM1 antibody. J Immunol 195(10):4973–4985. https://doi.org/10.4049/jimmunol.1500651CrossRefPubMed

89.

Turner JE, Becker M, Mittrücker HW, Panzer U (2018) Tissue-resident lymphocytes in the kidney. J Am Soc Nephrol 29(2):389–399. https://doi.org/10.1681/ASN.2017060599CrossRefPubMed

90.

Zhang Z-X, Wang S, Huang X, Min W-P, Sun H, Liu W, Garcia B, Jevnikar AM (2008) NK Cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia-reperfusion injury. J Immunol 181(11):7489–7498. https://doi.org/10.4049/jimmunol.181.11.7489CrossRefPubMed

91.

Luo L, Lu J, Wei L, Long D, Guo JY, Shan J, Fu S, Li FS, Lu PY, Li PY, Feng L (2010) The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation. BMC Cell Biol 11:91. https://doi.org/10.1186/1471-2121-11-91CrossRefPubMedPubMedCentral

92.

Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A (2011) Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 44(14–15):1189–1198. https://doi.org/10.1016/j.clinbiochem.2011.06.988CrossRefPubMed

93.

Losappio V, Franzin R, Infante B, Godeas G, Gesualdo L, Fersini A, Castellano G, Stallone G (2020) Molecular mechanisms of premature aging in hemodialysis: the complex interplay between innate and adaptive immune dysfunction. Int J Mol Sci 21(10):3422. https://doi.org/10.3390/ijms21103422CrossRefPubMedCentral

94.

Sanchis P, Ho CY, Liu Y, Beltran LE, Ahmad S, Jacob AP, Furmanik M, Laycock J, Long DA, Shroff R, Shanahan CM (2019) Arterial “inflammaging” drives vascular calcification in children on dialysis. Kidney Int 95(4):958–972. https://doi.org/10.1016/j.kint.2018.12.014CrossRefPubMedPubMedCentral

95.

Sepe V, Rampino T, Libetta C (2019) Arterial, “inflammaging” drives vascular calcification in children on dialysis. Kidney Int 96(2):522. https://doi.org/10.1016/j.kint.2019.05.021CrossRefPubMed

96.

Desai AA, Nissenson A, Chertow GM, Farid M, Singh I, Van Oijen MG, Esrailian E, Solomon MD, Spiegel BM (2009) The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: a systematic review. Hemodial Int 13(3):347–359. https://doi.org/10.1111/j.1542-4758.2009.00377.xCrossRefPubMed

97.

Li PK, Ng JK, Mcintyre CW (2017) Inflammation and peritoneal dialysis. Semin Nephrol 37(1):54–65. https://doi.org/10.1016/j.semnephrol.2016.10.007CrossRefPubMed

98.

Elmarakby AA, Sullivan JC (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30(1):49–59. https://doi.org/10.1111/j.1755-5922.2010.00218.xCrossRefPubMed

99.

Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Kalantar-Zadeh K (2011) Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr 21(1):100–104. https://doi.org/10.1053/j.jrn.2010.10.006CrossRefPubMedPubMedCentral

100.

Gandolfini I, Regolisti G, Bazzocchi A, Maggiore U, Palmisano A, Piotti G, Fiaccadori E, Sabatino A (2019) Frailty and sarcopenia in older patients receiving kidney transplantation. Front Nutr 6:169. https://doi.org/10.3389/fnut.2019.00169CrossRefPubMedPubMedCentral

101.

Fuery MA, Liang L, Kaplan FS, Mohler ER 3rd (2018) Vascular ossification: pathology, mechanisms, and clinical implications. Bone 109:28–34. https://doi.org/10.1016/j.bone.2017.07.006CrossRefPubMed

102.

Düsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, Jansen F (2021) Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med (Berl) 99(3):335–348. https://doi.org/10.1007/s00109-021-02037-7CrossRef

103.

López-Mejías R, González-Gay MA (2019) IL-6: linking chronic inflammation and vascular calcification. Nat Rev Rheumatol 15(8):457–459. https://doi.org/10.1038/s41584-019-0259-xCrossRefPubMed

104.

Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, Valente M, Garrone A, Islam T, Libetta C, Sepe V, Albertini R, Bruno R, Belliato M (2020) Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. https://doi.org/10.1159/000511725CrossRefPubMed

105.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97(5):829–838. https://doi.org/10.1016/j.kint.2020.03.005CrossRefPubMedPubMedCentral

106.

Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, Canetta P, Lloyd E, Ratner LE, Marasa M, Gharavi AG, Stokes MB, Markowitz GS, D’Agati VD (2020) Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. https://doi.org/10.1681/ASN.2020060802CrossRefPubMedPubMedCentral

107.

George JA, Khoza S (2021) SARS-CoV-2 infection and the kidneys: an evolving picture. Adv Exp Med Biol 1327:107–118. https://doi.org/10.1007/978-3-030-71697-4_8CrossRefPubMed

108.

D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, Choi HK (2021) COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 73(6):914–920. https://doi.org/10.1002/art.41619CrossRefPubMed

109.

Yazdanpanah N, Rezaei N (2021) Autoimmune Complications of COVID-19. J Med Virol. https://doi.org/10.1002/jmv.27292CrossRefPubMedPubMedCentral

110.

Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, van der Voort PH, Mulder DJ, van Goor H (2020) Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 251(3):228–248. https://doi.org/10.1002/path.5471CrossRefPubMed

111.

Raby AC, González-Mateo GT, Williams A, Topley N, Fraser D, López-Cabrera M, Labéta MO (2018) Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis. Kidney Int 94(2):346–362. https://doi.org/10.1016/j.kint.2018.03.014CrossRefPubMed

112.

Kim HJ, Park SJ, Koo S, Cha HJ, Lee JS, Kwon B, Cho HR (2014) Inhibition of kidney ischemia-reperfusion injury through local infusion of a TLR2 blocker. J Immunol Methods 407:146–150. https://doi.org/10.1016/j.jim.2014.03.014CrossRefPubMed

113.

Farrar CA, Keogh B, McCormack W, O’Shaughnessy A, Parker A, Reilly M, Sacks SH (2012) Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J 26(2):799–807. https://doi.org/10.1096/fj.11-195396CrossRefPubMed

114.

Chen X, Ma J, Kwan T, Stribos EGD, Messchendorp AL, Loh YW, Wang X, Paul M, Cunningham EC, Habib M, Alexander IE, Sharland AF, Chadban SJ, Wu H (2018) Blockade of HMGB1 attenuates diabetic nephropathy in mice. Sci Rep 8(1):8319. https://doi.org/10.1038/s41598-018-26637-5CrossRefPubMedPubMedCentral

115.

Prattichizzo F, Giuliani A, Recchioni R, Bonafè M, Marcheselli F, De Carolis S, Campanati A, Giuliodori K, Rippo MR, Brugè F, Tiano L, Micucci C, Ceriello A, Offidani A, Procopio AD, Olivieri F (2016) Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. Oncotarget 7(11):1945–1958. https://doi.org/10.18632/oncotarget.7858CrossRef

116.

Xi T, Jin F, Zhu Y, Wang J, Tang L, Wang Y, Liebeskind DS, He Z (2017) MicroRNA-126-3p attenuates blood-brain barrier disruption, cerebral edema and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and Akt. Biochem Biophys Res Commun 494(1–2):144–151CrossRefPubMed

117.

Gregorini M, Maccario R, Avanzini MA, Corradetti V, Moretta A, Libetta C, Esposito P, Bosio F, Dal Canton A, Rampino T (2013) Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: Evaluation of the contribution of immune-mediated mechanisms. Mayo Clin Proc 88(10):1174–1179. https://doi.org/10.1016/j.mayocp.2013.06.021CrossRefPubMed

Titel: The innate immune system in human kidney inflammaging
verfasst von: Vincenzo Sepe
Carmelo Libetta
Marilena Gregorini
Teresa Rampino
Publikationsdatum: 26.11.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Journal of Nephrology / Ausgabe 2/2022
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-021-01153-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The innate immune system in human kidney inflammaging

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Serum sodium trajectory during AKI and mortality risk

Estimation of childhood nephrotic syndrome incidence: data from the atlanta metropolitan statistical area and meta-analysis of worldwide cases

The role of Plasma Renin Activity in prenatally diagnosed non-obstructed hydronephrosis at risk for surgery—an observational study

NGAL/hepcidin-25 ratio and AKI subtypes in patients following cardiac surgery: a prospective observational study

The disasters of war. On kidney patients in the Ukrainian–Russian war

Granulomatosis with polyangiitis mimicking cancer: a diagnostic dilemma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin